Skip to content

A study to compare the effect of patoladi kwath and hapushadi yapan vasti in vatarakta(gouty arthritis)

A comparative study of patoladi kwath and hapushadi yapan vasti in vatarakta

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025355
Enrollment
40
Registered
2020-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M10- Gout

Interventions

Intervention1: group A(Patoladi kwath): 20 patients will be treated with patoladi kwath(patola, katuki, shatavari, haritaki, vibhitaki, amalaki,giloy) freshly prepared twice a day and administered in

Sponsors

tanushree
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Well diagnosed patients of Vatarakta. (Diagnosis will be made on the basis of assessment criteria as mentioned in classical texts & modern medical science.) Both previously treated and fresh cases will be taken. Patients of either sex. Increased serum uric acid levels of more than 7mg/dl in males and 6mg/dl in females.

Exclusion criteria

Exclusion criteria: Patients of Vatarakta with any chronic systemic disorder which interferes with the present study. Patients of age below 18 or more than 70 years. Patients of Vatarakta having any severe arthritic condition (like R.A.) will be excluded . Patients of Vatarakta with conditions like haemarthrosis, Kochâ??s arthritis, septic arthritis, chronic kidney disease. Patients with serious medical illness and psychiatric disorder will be excluded. Cases with alcohol dependence/ misuse and drug abuse. Pregnancy.

Design outcomes

Primary

MeasureTime frame
reduction in subjective parameters according to the specific grading given to each symptoms like burning, pain, skin discoloration, redness, stiffness, tenderness, numbness, heaviness, swelling, deformity in joint involved and pain on joint movement. no sign-0 mild-1 moderate-2 severe-3 Also reduction in objective parameters of serum uric acid.Timepoint: the patient will be followed up at every 15 days for one month after completion of treatment.

Secondary

MeasureTime frame
reduction in erythrocyte sedimentation rate. exacerbation of symptoms.Timepoint: the patient will be followed up at every 15 days after completion of treatment.

Countries

India

Contacts

Public ContactDr Dinesh Kumar Goyal

Gurukul campus, uttarakhand ayurveda university

dineshdr157@gmail.com9411731180

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026